A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
出版年份 2019 全文链接
标题
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer
作者
关键词
Active cancer immunotherapy, mRNA, Non-small cell lung cancer, Immunomonitoring, Clinical trial, CV9201
出版物
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2019-02-15
DOI
10.1007/s00262-019-02315-x
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Safety and immunogenicity of a mRNA rabies vaccine in healthy adults: an open-label, non-randomised, prospective, first-in-human phase 1 clinical trial
- (2017) Martin Alberer et al. LANCET
- Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
- (2017) Matthew D Hellmann et al. LANCET ONCOLOGY
- Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses
- (2017) Kapil Bahl et al. MOLECULAR THERAPY
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- Unmodified mRNA in LNPs constitutes a competitive technology for prophylactic vaccines
- (2017) Johannes Lutz et al. npj Vaccines
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2016) Johan F Vansteenkiste et al. LANCET ONCOLOGY
- Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
- (2016) Lena M. Kranz et al. NATURE
- Distinct transcriptional changes in non-small cell lung cancer patients associated with multi-antigenic RNActive® CV9201 immunotherapy
- (2016) Henoch S. Hong et al. OncoImmunology
- A phase III study of belagenpumatucel-L, an allogeneic tumour cell vaccine, as maintenance therapy for non-small cell lung cancer
- (2015) G. Giaccone et al. EUROPEAN JOURNAL OF CANCER
- Overall Survival and Long-Term Safety of Nivolumab (Anti–Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer
- (2015) Scott N. Gettinger et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survivin – The inconvenient IAP
- (2015) Dario C. Altieri SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Long-term survival correlates with immunological responses in renal cell carcinoma patients treated with mRNA-based immunotherapy
- (2015) Susanne M. Rittig et al. OncoImmunology
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study
- (2015) Hubert Kübler et al. Journal for ImmunoTherapy of Cancer
- Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer
- (2014) Martin Sebastian et al. BMC CANCER
- A phase I dose escalation trial of MAGE-A3- and HPV16-specific peptide immunomodulatory vaccines in patients with recurrent/metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN)
- (2014) Dan P. Zandberg et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- B Cell–Intrinsic TLR7 Signaling Is Essential for the Development of Spontaneous Germinal Centers
- (2014) Chetna Soni et al. JOURNAL OF IMMUNOLOGY
- A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome
- (2014) Shoichi Hazama et al. Journal of Translational Medicine
- Antibody response to cancer/testis (CT) antigens: A prognostic marker in cancer patients
- (2014) Yoshihiro Ohue et al. OncoImmunology
- Analysis of GAGE, NY-ESO-1 and SP17 cancer/testis antigen expression in early stage non-small cell lung carcinoma
- (2013) Morten F Gjerstorff et al. BMC CANCER
- Long-term Vaccination with Multiple Peptides Derived from Cancer-Testis Antigens Can Maintain a Specific T-cell Response and Achieve Disease Stability in Advanced Biliary Tract Cancer
- (2013) A. Aruga et al. CLINICAL CANCER RESEARCH
- Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-A-Specific T Cells
- (2013) B. Weide et al. CLINICAL CANCER RESEARCH
- Maintenance Chemotherapy for Advanced Non–Small-Cell Lung Cancer: New Life for an Old Idea
- (2013) David E. Gerber et al. JOURNAL OF CLINICAL ONCOLOGY
- Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial
- (2013) Charles Butts et al. LANCET ONCOLOGY
- Highly potent mRNA based cancer vaccines represent an attractive platform for combination therapies supporting an improved therapeutic effect
- (2012) Mariola Fotin-Mleczek et al. JOURNAL OF GENE MEDICINE
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- Prognostic Value of Survivin in Patients with Non-Small Cell Lung Carcinoma: A Systematic Review with Meta-Analysis
- (2012) Lou Qian Zhang et al. PLoS One
- Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells
- (2011) M. Damelin et al. CANCER RESEARCH
- Serum is not required for ex vivo IFN-γ ELISPOT: a collaborative study of different protocols from the European CIMT Immunoguiding Program
- (2010) A. Mander et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- CD19+CD24hiCD38hi B Cells Exhibit Regulatory Capacity in Healthy Individuals but Are Functionally Impaired in Systemic Lupus Erythematosus Patients
- (2010) Paul A. Blair et al. IMMUNITY
- Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity
- (2010) Mariola Fotin-Mleczek et al. JOURNAL OF IMMUNOTHERAPY
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
- (2010) Susanne M Rittig et al. MOLECULAR THERAPY
- Novel Human Transitional B Cell Populations Revealed by B Cell Depletion Therapy
- (2009) Arumugam Palanichamy et al. JOURNAL OF IMMUNOLOGY
- Direct Injection of Protamine-protected mRNA: Results of a Phase 1/2 Vaccination Trial in Metastatic Melanoma Patients
- (2009) Benjamin Weide et al. JOURNAL OF IMMUNOTHERAPY
- Results of the First Phase I/II Clinical Vaccination Trial With Direct Injection of mRNA
- (2008) Benjamin Weide et al. JOURNAL OF IMMUNOTHERAPY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More